Pruritus is also referred to as itch disorder triggered by several other disorders ranging from dermatological disorders such as contact dermatitis, mycoses, atopic dermatitis, and chickenpox. Pruritus is associated with dermatologic and systemic causes. A typical itching is the diagnosis of a primary dermatologic syndrome. Many skin diseases related to pruritus include renal pruritus, endocrine pruritus, hematologic pruritus, cholestatic pruritus, idiopathic generalized pruritus, and pruritus to malignancy. Increased levels of ions such as calcium, magnesium, and phosphate, are found in the skin of pruritic patients. Severe pruritus can result in scratching that causes secondary skin problems such as eczema, lichenification, dryness, infection, excoriation, contact allergy, and others.
Top Driver: Rising Prevalence and Strategic Actions of Significant Players
The rising prevalence of dermatological disorder influencing the occurrence of pruritus and consecutively, the surging demand for proper diagnostics and therapeutics to treat such medical conditions is estimated to drive the market growth. The emergence in inorganic development strategies is one of the major factors boosting the growth of the pruritus therapeutics market. In addition to this, the significant players of the pruritus therapeutics market are rapidly adapting the growth strategies such as mergers & acquisitions, partnerships, regional acquirements. These growth strategies are anticipated to stimulate technological advancement due to enhanced product portfolio and collaboration in R & D, further propelling the market growth.
Corticosteroid Segment Accounts for the Largest Market Share
The global Pruritus Therapeutics market is segmented into corticosteroids, antihistamines, local anesthetics, and others based on the product. Corticosteroids dominated the pruritus therapeutics and are anticipated to continue the trend during the forecast period. Corticosteroids are generally used as the first line of treatment. On the other hand, calcineurin inhibitors are expected to grow at the significant CAGR during the forecast period due to its high response rate and presence of a strong pipeline of calcineurin inhibitors and semi-synthetic analogs of these inhibitors. Based on the disease type, the market is segmented into atopic dermatitis, allergic contact dermatitis, urticaria, and others.

Government Initiatives and the Development of New Products to Benefit North America Market
On the basis of region, the global pruritus therapeutics market is segmented into North America, Europe, Asia Pacific, and SAMEA. North America was estimated to hold largest market share in the global pruritus therapeutics market. The dominance is majorly owing to the presence of government initiatives and the development of new products. Besides, rising incidence of target disorders and the presence of pruritus inducing climatic disorders in this region are estimated to boost the market growth during the forecast period. However, Asia Pacific is anticipated to dominate pruritus therapeutics market. Rising incidence of atopic dermatitis and urticarial and presence of unmet healthcare organization needs are the factors driving the growth of the market in Asia Pacific.

Players to Focus on Acquisition and Product Development
The major players operating in the global pruritus therapeutics market are Allergen, Bristol-Myers Squibb, Astellas Pharma, GlaxoSmithKline, Eli Lilly, Novartis, Merck, Sanofi, and Pfizer.
Allergan plc: Allergan plc announced that they have entered into a definitive agreement under which Allergan will acquire Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The acquisition will strengthen Allergan’s dermatology product pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active ROR?t inhibitor for the potential treatment of psoriasis and other autoimmune disorders.
Amgen: In October 2018, Amgen announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS), and other disorders.
Scope of the Report
By Product Type
” Corticosteroid
” Antihistamines
” Local anesthetics
” Others

By Disease type
” Atopic dermatitis
” Allergic contact dermatitis
” Urticaria
” Others

By Region
” North America
” Europe
” Asia Pacific
” LAMEA

Key Reasons to Purchase this Report
1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.